DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes
详细信息 查看全文
- 作者：Gian Paolo Fadini ; Benedetta Maria Bonora ; Mattia Albiero…
- 关键词：Heart failure ; Enzyme ; Proteases ; Linagliptin ; Kidney disease
- 刊名：Cardiovascular Diabetology
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：16
- 期：1
- 全文大小：1024KB
- 刊物主题：Diabetes; Angiology; Cardiology;
- 出版者：BioMed Central
- ISSN：1475-2840
- 卷排序：16
文摘
BackgroundUse of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a substrate of DPP-4. We herein tested the acute effects of the DPP-4i linagliptin on BNP and NT-proBNP in a cross-over placebo-controlled trial in patients with T2D with and without chronic kidney disease (CKD).